ClinicalTrials.gg

Program

BB102

A development code. Also written as “BB102 tablet”.

Its studies are mostly in Carcinoma, Hepatocellular, led by Broadenbio.

Furthest: phase 2, since Nov 14, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Broadenbio22 open or runningphase 2since Nov 14, 2025Feb 6, 2024Dec 2026phase 1 · NCT06258408

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 6, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06258408 · 78 planned · China
  2. Nov 14, 2025Phase 2 study in Carcinoma, HepatocellularNCT07239986 · 60 planned · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in Advanced Solid TumorNCT06258408
  2. Jun 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07239986

TargetBeta

FGFR4 →read by rule
“This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma.”study text, by rule · the study

Other programs on FGFR4

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
infigratinibruleBridgeBiophase 317
futibatinibruleOtsukaphase 310
irpagratinibruleAbbisko Caymanphase 26

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07239986Carcinoma, Hepatocellular · China2Not yet recruitingJun 202760
NCT06258408Advanced Solid Tumor · China1RecruitingDec 202678

How it is read

Names in the registry

  • “BB102”, 1 entry
  • “BB102 tablet”, 1 entry

Codes read as this program: BB102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.